Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference
Olema Oncology (Nasdaq: OLMA) announced that CEO Sean P. Bohen, M.D., Ph.D. will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 2:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Olema Oncology (Nasdaq: OLMA) announced that CEO Sean P. Bohen, M.D., Ph.D. will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 2:30 p.m. ET. A live webcast and recording will be available on Olema’s investor relations site, subject to event host permissions.
Details
News Market Reaction – OLMA
On Feb 20, the first trading day after this news, OLMA closed 1.13% above the previous close.
Data tracked by StockTitan Argus for the Feb 20 session.
Key Figures
- Conference edition
- 46th Annual
- TD Cowen Health Care Conference
- Presentation date
- March 3, 2026
- Scheduled conference presentation
- Presentation time
- 2:30 p.m. ET
- TD Cowen conference slot
- Current price
- $23.81
- Pre-news trading level
- 24h price change
- 5.13%
- Move ahead of/around conference news
- 52-week low
- $2.86
- Versus current $23.81
- 52-week high
- $36.2591
- Stock trading 34.33% below this level
- Market cap
- $1,796,383,874
- Pre-news valuation
Historical Context
-
Outlined participation in three February 2026 investor conferences.
-
Granted options for 24,000 shares to two new employees under inducement plan.
-
COO/CFO departure with CEO assuming interim principal financial officer role.
-
Issued options for 223,500 shares to eight new employees at $25.28 exercise price.
-
Announced presentation at J.P. Morgan Healthcare Conference with webcast access.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 2:30 p.m. ET.
A live webcast and recording of this presentation will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.